Clinical Trials Arena on MSN
IntraBio’s ataxia-telangiectasia drug meets endpoints in pivotal trial
If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.
BOSTON, July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a ...
Dysdiadochokinesia is the inability to perform quick, alternating movements, such as opening and closing a fist or tapping a foot. It is usually a symptom of an underlying health condition that ...
Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.
News Medical on MSN
CIRM awards $7.4 million to advance stem cell-based gene therapy for Friedreich's ataxia
The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback